{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:15:36Z","timestamp":1790388936681,"version":"4.1.0"},"reference-count":75,"publisher":"American Association for Cancer Research (AACR)","issue":"4","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA155258-10"],"award-info":[{"award-number":["CA155258-10"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>The oncogenic transcription factor (TF) IRF4 is a currently undrugged universal multiple myeloma dependency. Using transcriptional regulatory network mapping, an unbiased multiomics target ID approach, we identified the coactivator lysine acetyltransferase (KAT) p300 as a key IRF4 partner. Validation of this preferential relationship through quantitative interactome mapping revealed that IRF4 was the most abundant multiple myeloma\u2013specific dependency and more closely complexed with p300 than other TFs, such as IKZF1\/IKZF3. Development of optimized p300 KAT inhibitors enabled inhibition of IRF4 activity and multiple myeloma proliferation ex vivo and in vivo. p300\/CBP KAT inhibition preferentially targeted multiple myeloma cells over normal cells, specifically modulating the multiple myeloma transcriptome, and the p300 KAT inhibitors more completely inhibited IRF4 activity at lower levels compared with existing p300\/CREB-binding protein (CBP) bromodomain inhibitors. Furthermore, combining p300\/CBP KAT inhibition and therapeutics with orthogonal mechanisms targeting transcription in multiple myeloma elicited synergistic antitumor effects. Together, these data motivate the ongoing clinical development of p300\/CBP KAT inhibition in multiple myeloma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Inhibition of p300 lysine acetyltransferase activity preferentially modulates the IRF4 transcriptional regulatory network and is orthogonal to mechanisms of multiple myeloma standard-of-care treatment, supporting the translational potential of p300 inhibitors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/0008-5472.can-25-3440","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T21:48:53Z","timestamp":1763416133000},"page":"1010-1034","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma"],"prefix":"10.1158","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7413-1885","authenticated-orcid":false,"given":"W. Frank","family":"Lenoir","sequence":"first","affiliation":[{"name":"1Kronos Bio, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4537-1133","authenticated-orcid":false,"given":"Michael R.","family":"McKeown","sequence":"additional","affiliation":[{"name":"1Kronos Bio, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7494-0154","authenticated-orcid":false,"given":"Giulia","family":"Giorgetti","sequence":"additional","affiliation":[{"name":"2Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4569-7394","authenticated-orcid":false,"given":"Marek J.","family":"Kobylarz","sequence":"additional","affiliation":[{"name":"1Kronos Bio, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7767-5246","authenticated-orcid":false,"given":"Tamara D.","family":"Hopkins","sequence":"additional","affiliation":[{"name":"1Kronos Bio, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8291-7825","authenticated-orcid":false,"given":"Wayne L.","family":"Glore","sequence":"additional","affiliation":[{"name":"1Kronos Bio, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4625-5918","authenticated-orcid":false,"given":"Michelle G.","family":"Shum","sequence":"additional","affiliation":[{"name":"1Kronos Bio, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1207-6160","authenticated-orcid":false,"given":"Yaretzi","family":"Calder\u00f3n","sequence":"additional","affiliation":[{"name":"1Kronos Bio, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4479-9822","authenticated-orcid":false,"given":"Jessica","family":"Encinas Mayoral","sequence":"additional","affiliation":[{"name":"2Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0517-0727","authenticated-orcid":false,"given":"Luis A.","family":"Carvajal","sequence":"additional","affiliation":[{"name":"1Kronos Bio, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1474-2898","authenticated-orcid":false,"given":"Kameron R.","family":"Mori","sequence":"additional","affiliation":[{"name":"1Kronos Bio, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9940-3421","authenticated-orcid":false,"given":"Jun","family":"Li","sequence":"additional","affiliation":[{"name":"1Kronos Bio, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7148-8179","authenticated-orcid":false,"given":"Hua","family":"Gao","sequence":"additional","affiliation":[{"name":"1Kronos Bio, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4599-6346","authenticated-orcid":false,"given":"Yupeng","family":"Zheng","sequence":"additional","affiliation":[{"name":"1Kronos Bio, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9626-5614","authenticated-orcid":false,"given":"Zhihua","family":"Ma","sequence":"additional","affiliation":[{"name":"1Kronos Bio, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4833-9971","authenticated-orcid":false,"given":"Nikolaus D.","family":"Obholzer","sequence":"additional","affiliation":[{"name":"1Kronos Bio, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4903-3818","authenticated-orcid":false,"given":"Minyun","family":"Zhou","sequence":"additional","affiliation":[{"name":"1Kronos Bio, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6780-0358","authenticated-orcid":false,"given":"Benjamin W.","family":"Trotter","sequence":"additional","affiliation":[{"name":"1Kronos Bio, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9795-2393","authenticated-orcid":false,"given":"Christopher J.","family":"Dinsmore","sequence":"additional","affiliation":[{"name":"1Kronos Bio, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7344-9795","authenticated-orcid":false,"given":"Nikhil C.","family":"Munshi","sequence":"additional","affiliation":[{"name":"2Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9155-090X","authenticated-orcid":false,"given":"Charles Y.","family":"Lin","sequence":"additional","affiliation":[{"name":"1Kronos Bio, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1432-9742","authenticated-orcid":false,"given":"Mariateresa","family":"Fulciniti","sequence":"additional","affiliation":[{"name":"2Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8932-9483","authenticated-orcid":false,"given":"Peter B.","family":"Rahl","sequence":"additional","affiliation":[{"name":"1Kronos Bio, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"2026021911383851700_bib1","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.3390\/curroncol30020179","article-title":"Relapsed\/refractory multiple myeloma: a review of available therapies and clinical scenarios encountered in myeloma relapse","volume":"30","author":"Bhatt","year":"2023","journal-title":"Curr Oncol"},{"key":"2026021911383851700_bib2","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/nrclinonc.2014.200","article-title":"Current treatment landscape for relapsed and\/or refractory multiple myeloma","volume":"12","author":"Dimopoulos","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"2026021911383851700_bib3","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am J Hematol"},{"key":"2026021911383851700_bib4","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1182\/blood-2010-04-279596","article-title":"A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value","volume":"116","author":"Walker","year":"2010","journal-title":"Blood"},{"key":"2026021911383851700_bib5","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nature09837","article-title":"Initial genome sequencing and analysis of multiple myeloma","volume":"471","author":"Chapman","year":"2011","journal-title":"Nature"},{"key":"2026021911383851700_bib6","first-page":"2841","article-title":"CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma","volume":"141","author":"Yao","year":"2023","journal-title":"Blood"},{"key":"2026021911383851700_bib7","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.3324\/haematol.2013.090142","article-title":"High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib","volume":"99","author":"Gambella","year":"2014","journal-title":"Haematologica"},{"key":"2026021911383851700_bib8","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/ng.3984","article-title":"Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells","volume":"49","author":"Meyers","year":"2017","journal-title":"Nat Genet"},{"key":"2026021911383851700_bib9","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","article-title":"Defining a cancer dependency map","volume":"170","author":"Tsherniak","year":"2017","journal-title":"Cell"},{"key":"2026021911383851700_bib10","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1186\/s13059-021-02540-7","article-title":"Chronos: a cell population dynamics model of CRISPR experiments that improves inference of gene fitness effects","volume":"22","author":"Dempster","year":"2021","journal-title":"Genome Biol"},{"key":"2026021911383851700_bib11","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/s43018-023-00550-x","article-title":"Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias","volume":"4","author":"de Matos Simoes","year":"2023","journal-title":"Nat Cancer"},{"key":"2026021911383851700_bib12","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature07064","article-title":"IRF4 addiction in multiple myeloma","volume":"454","author":"Shaffer","year":"2008","journal-title":"Nature"},{"key":"2026021911383851700_bib13","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41408-019-0173-0","article-title":"Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4","volume":"9","author":"Zhu","year":"2019","journal-title":"Blood Cancer J"},{"key":"2026021911383851700_bib14","doi-asserted-by":"crossref","first-page":"112917","DOI":"10.18632\/oncotarget.22872","article-title":"Role of IRF4 in resistance to immunomodulatory (IMid) compounds\u00ae in Waldenstr\u00f6m's macroglobulinemia","volume":"8","author":"Bertrand","year":"2017","journal-title":"Oncotarget"},{"key":"2026021911383851700_bib15","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.cell.2016.12.013","article-title":"Transcriptional addiction in cancer","volume":"168","author":"Bradner","year":"2017","journal-title":"Cell"},{"key":"2026021911383851700_bib16","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.molcel.2014.08.024","article-title":"NF-\u03baB directs dynamic super enhancer formation in inflammation and atherogenesis","volume":"56","author":"Brown","year":"2014","journal-title":"Mol Cell"},{"key":"2026021911383851700_bib17","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/nature21688","article-title":"Transcription control by the ENL YEATS domain in acute leukaemia","volume":"543","author":"Erb","year":"2017","journal-title":"Nature"},{"key":"2026021911383851700_bib18","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nature21687","article-title":"ENL links histone acetylation to oncogenic gene expression in acute myeloid leukaemia","volume":"543","author":"Wan","year":"2017","journal-title":"Nature"},{"key":"2026021911383851700_bib19","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1101\/gad.244368.114","article-title":"CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma","volume":"28","author":"Huang","year":"2014","journal-title":"Genes Dev"},{"key":"2026021911383851700_bib20","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1158\/2643-3230.BCD-23-0062","article-title":"Transcriptional heterogeneity overcomes super-enhancer disrupting drug combinations in multiple myeloma","volume":"5","author":"Welsh","year":"2024","journal-title":"Blood Cancer Discov"},{"key":"2026021911383851700_bib21","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1101\/gr.197590.115","article-title":"Models of human core transcriptional regulatory circuitries","volume":"26","author":"Saint-Andr\u00e9","year":"2016","journal-title":"Genome Res"},{"key":"2026021911383851700_bib22","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nature16546","article-title":"Active medulloblastoma enhancers reveal subgroup-specific cellular origins","volume":"530","author":"Lin","year":"2016","journal-title":"Nature"},{"key":"2026021911383851700_bib23","doi-asserted-by":"crossref","first-page":"100188","DOI":"10.1016\/j.xcrm.2020.100188","article-title":"Targeted brachyury degradation disrupts a highly specific autoregulatory program controlling chordoma cell identity","volume":"2","author":"Sheppard","year":"2021","journal-title":"Cell Rep Med"},{"key":"2026021911383851700_bib24","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1158\/2643-3230.BCD-21-0207","article-title":"Transcriptional plasticity drives leukemia immune escape","volume":"3","author":"Eagle","year":"2022","journal-title":"Blood Cancer Discov"},{"key":"2026021911383851700_bib25","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.stem.2022.01.003","article-title":"An oncogenic enhancer encodes selective selenium dependency in AML","volume":"29","author":"Eagle","year":"2022","journal-title":"Cell Stem Cell"},{"key":"2026021911383851700_bib26","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1016\/j.molcel.2021.04.015","article-title":"Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300\/CBP inhibition","volume":"81","author":"Hogg","year":"2021","journal-title":"Mol Cell"},{"key":"2026021911383851700_bib27","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nature24028","article-title":"Discovery of a selective catalytic p300\/CBP inhibitor that targets lineage-specific tumours","volume":"550","author":"Lasko","year":"2017","journal-title":"Nature"},{"key":"2026021911383851700_bib28","doi-asserted-by":"crossref","first-page":"e10483","DOI":"10.7554\/eLife.10483","article-title":"Bromodomain inhibition of the transcriptional coactivators CBP\/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma","volume":"5","author":"Conery","year":"2016","journal-title":"Elife"},{"key":"2026021911383851700_bib29","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-021-00421-7","article-title":"Myeloma-specific superenhancers affect genes of biological and clinical relevance in myeloma","volume":"11","author":"Jia","year":"2021","journal-title":"Blood Cancer J"},{"key":"2026021911383851700_bib30","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1182\/blood-2017-09-808063","article-title":"Active enhancer and chromatin accessibility landscapes chart the regulatory network of primary multiple myeloma","volume":"131","author":"Jin","year":"2018","journal-title":"Blood"},{"key":"2026021911383851700_bib31","doi-asserted-by":"crossref","first-page":"9354","DOI":"10.1038\/s41598-019-45839-z","article-title":"The ENCODE blacklist: identification of problematic regions of the genome","volume":"9","author":"Amemiya","year":"2019","journal-title":"Sci Rep"},{"key":"2026021911383851700_bib32","doi-asserted-by":"crossref","first-page":"D638","DOI":"10.1093\/nar\/gkac1000","article-title":"The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest","volume":"51","author":"Szklarczyk","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"2026021911383851700_bib33","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.cell.2013.09.053","article-title":"Super-enhancers in the control of cell identity and disease","volume":"155","author":"Hnisz","year":"2013","journal-title":"Cell"},{"key":"2026021911383851700_bib34","doi-asserted-by":"crossref","first-page":"e201800278","DOI":"10.26508\/lsa.201800278","article-title":"A network of human functional gene interactions from knockout fitness screens in cancer cells","volume":"2","author":"Kim","year":"2019","journal-title":"Life Sci Alliance"},{"key":"2026021911383851700_bib35","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1158\/2643-3230.BCD-23-0061","article-title":"ETV4-Dependent transcriptional plasticity maintains MYC expression and results in IMiD resistance in multiple myeloma","volume":"5","author":"Neri","year":"2024","journal-title":"Blood Cancer Discov"},{"key":"2026021911383851700_bib36","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","article-title":"Selective inhibition of tumor oncogenes by disruption of super-enhancers","volume":"153","author":"Lov\u00e9n","year":"2013","journal-title":"Cell"},{"key":"2026021911383851700_bib37","doi-asserted-by":"crossref","first-page":"e0166438","DOI":"10.1371\/journal.pone.0166438","article-title":"An alternative approach to ChIP-Seq normalization enables detection of genome-wide changes in histone H3 lysine 27 trimethylation upon EZH2 inhibition","volume":"11","author":"Egan","year":"2016","journal-title":"PLoS One"},{"key":"2026021911383851700_bib38","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.celrep.2014.10.018","article-title":"Quantitative ChIP-Seq normalization reveals global modulation of the epigenome","volume":"9","author":"Orlando","year":"2014","journal-title":"Cell Rep"},{"key":"2026021911383851700_bib39","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41588-018-0044-9","article-title":"Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma","volume":"50","author":"Zeid","year":"2018","journal-title":"Nat Genet"},{"key":"2026021911383851700_bib40","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1002\/imt2.43","article-title":"Complex heatmap visualization","volume":"1","author":"Gu","year":"2022","journal-title":"Imeta"},{"key":"2026021911383851700_bib41","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1038\/s41375-020-01078-0","article-title":"The transcription factor IRF4 represses proapoptotic BMF and BIM to licence multiple myeloma survival","volume":"35","author":"Fedele","year":"2021","journal-title":"Leukemia"},{"key":"2026021911383851700_bib42","first-page":"100141","article-title":"clusterProfiler 4.0: a universal enrichment tool for interpreting omics data","volume":"2","author":"Wu","year":"2021","journal-title":"Innovation (Camb)"},{"key":"2026021911383851700_bib43","doi-asserted-by":"crossref","first-page":"D679","DOI":"10.1093\/nar\/gkad960","article-title":"WikiPathways 2024: next generation pathway database","volume":"52","author":"Agrawal","year":"2024","journal-title":"Nucleic Acids Res"},{"key":"2026021911383851700_bib44","first-page":"995","article-title":"Development and characterization of a melphalan-resistant human multiple myeloma cell line","volume":"51","author":"Bellamy","year":"1991","journal-title":"Cancer Res"},{"key":"2026021911383851700_bib45","first-page":"4829","article-title":"Elimination of chemoresistant multiple myeloma clonogenic colony-forming cells by combined treatment with a plasma cell-reactive monoclonal antibody and a P-glycoprotein-reactive monoclonal antibody","volume":"49","author":"Tong","year":"1989","journal-title":"Cancer Res"},{"key":"2026021911383851700_bib46","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0301-472X(03)00023-7","article-title":"Characterization of the MM.1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells","volume":"31","author":"Greenstein","year":"2003","journal-title":"Exp Hematol"},{"key":"2026021911383851700_bib47","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1365-2141.2009.07647.x","article-title":"Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death","volume":"145","author":"Voorhees","year":"2009","journal-title":"Br J Haematol"},{"key":"2026021911383851700_bib48","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1182\/bloodadvances.2023012298","article-title":"Venetoclax resistance leads to broad resistance to standard-of-care anti-MM agents, but not to immunotherapies","volume":"8","author":"Deng","year":"2024","journal-title":"Blood Adv"},{"key":"2026021911383851700_bib49","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1093\/bfgp\/els065","article-title":"Cancers with wrong HATs: the impact of acetylation","volume":"12","author":"Di Cerbo","year":"2013","journal-title":"Brief Funct Genomics"},{"key":"2026021911383851700_bib50","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1021\/acsmedchemlett.0c00155","article-title":"Discovery of CPI-1612: a potent, selective, and orally bioavailable EP300\/CBP histone acetyltransferase inhibitor","volume":"11","author":"Wilson","year":"2020","journal-title":"ACS Med Chem Lett"},{"key":"2026021911383851700_bib51","doi-asserted-by":"crossref","first-page":"127854","DOI":"10.1016\/j.bmcl.2021.127854","article-title":"Discovery of spirohydantoins as selective, orally bioavailable inhibitors of p300\/CBP histone acetyltransferases","volume":"39","author":"Ji","year":"2021","journal-title":"Bioorg Med Chem Lett"},{"key":"2026021911383851700_bib52","doi-asserted-by":"crossref","first-page":"8669","DOI":"10.1021\/ja502372j","article-title":"Chemoproteomic profiling of lysine acetyltransferases highlights an expanded landscape of catalytic acetylation","volume":"136","author":"Montgomery","year":"2014","journal-title":"J Am Chem Soc"},{"key":"2026021911383851700_bib53","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.3390\/cells8091022","article-title":"Discordant effects of putative lysine acetyltransferase inhibitors in biochemical and living systems","volume":"8","author":"Henry","year":"2019","journal-title":"Cells"},{"key":"2026021911383851700_bib54","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/nature06546","article-title":"The structural basis of protein acetylation by the p300\/CBP transcriptional coactivator","volume":"451","author":"Liu","year":"2008","journal-title":"Nature"},{"key":"2026021911383851700_bib55","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1472-6807-14-2","article-title":"Dimeric structure of p300\/CBP associated factor","volume":"14","author":"Shi","year":"2014","journal-title":"BMC Struct Biol"},{"key":"2026021911383851700_bib56","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1107\/S0907444909047337","article-title":"XDS","volume":"66","author":"Kabsch","year":"2010","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"2026021911383851700_bib57","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1107\/S0907444910045749","article-title":"Overview of the CCP4 suite and current developments","volume":"67","author":"Winn","year":"2011","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"2026021911383851700_bib58","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1107\/S0907444910007493","article-title":"Features and development of Coot","volume":"66","author":"Emsley","year":"2010","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"2026021911383851700_bib59","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.chembiol.2023.07.005","article-title":"Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A\/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer","volume":"30","author":"Sharma","year":"2023","journal-title":"Cell Chem Biol"},{"key":"2026021911383851700_bib60","doi-asserted-by":"crossref","first-page":"8037","DOI":"10.1093\/nar\/gkab607","article-title":"HBO1 is a versatile histone acyltransferase critical for promoter histone acylations","volume":"49","author":"Xiao","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"2026021911383851700_bib61","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1007\/s13361-015-1179-x","article-title":"A deeper look into Comet\u2013implementation and features","volume":"26","author":"Eng","year":"2015","journal-title":"J Am Soc Mass Spectrom"},{"key":"2026021911383851700_bib62","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1038\/s41375-019-0403-2","article-title":"RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation","volume":"33","author":"Zhou","year":"2019","journal-title":"Leukemia"},{"key":"2026021911383851700_bib63","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1038\/s41467-021-22804-x","article-title":"Co-evolution of tumor and immune cells during progression of multiple myeloma","volume":"12","author":"Liu","year":"2021","journal-title":"Nat Commun"},{"key":"2026021911383851700_bib64","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.chembiol.2020.12.004","article-title":"Targeted degradation of the enhancer lysine acetyltransferases CBP and p300","volume":"28","author":"Vannam","year":"2021","journal-title":"Cell Chem Biol"},{"key":"2026021911383851700_bib65","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.ccell.2024.05.026","article-title":"IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma","volume":"42","author":"Bolomsky","year":"2024","journal-title":"Cancer Cell"},{"key":"2026021911383851700_bib66","doi-asserted-by":"crossref","first-page":"a026534","DOI":"10.1101\/cshperspect.a026534","article-title":"Exploitation of EP300 and CREBBP lysine acetyltransferases by cancer","volume":"7","author":"Attar","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2026021911383851700_bib67","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/j.1474-9726.2009.00503.x","article-title":"Calorie restriction alters mitochondrial protein acetylation","volume":"8","author":"Schwer","year":"2009","journal-title":"Aging Cell"},{"key":"2026021911383851700_bib68","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/cr.2011.22","article-title":"Regulation of chromatin by histone modifications","volume":"21","author":"Bannister","year":"2011","journal-title":"Cell Res"},{"key":"2026021911383851700_bib69","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.cell.2018.04.033","article-title":"Time-resolved analysis reveals rapid dynamics and broad scope of the CBP\/p300 acetylome","volume":"174","author":"Weinert","year":"2018","journal-title":"Cell"},{"key":"2026021911383851700_bib70","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1126\/science.ade3925","article-title":"Decrypting drug actions and protein modifications by dose- and time-resolved proteomics","volume":"380","author":"Zecha","year":"2023","journal-title":"Science"},{"key":"2026021911383851700_bib71","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4161\/epi.5.1.10449","article-title":"Target gene context influences the transcriptional requirement for the KAT3 family of CBP and p300 histone acetyltransferases","volume":"5","author":"Bedford","year":"2010","journal-title":"Epigenetics"},{"key":"2026021911383851700_bib72","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1038\/s41467-024-47793-5","article-title":"Bone marrow stromal cells induce chromatin remodeling in multiple myeloma cells leading to transcriptional changes","volume":"15","author":"Binder","year":"2024","journal-title":"Nat Commun"},{"key":"2026021911383851700_bib73","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/nm.2112","article-title":"Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity","volume":"16","author":"McMillin","year":"2010","journal-title":"Nat Med"},{"key":"2026021911383851700_bib74","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1177\/0192623319898469","article-title":"Preclinical safety assessment of a highly selective and potent dual small-molecule inhibitor of CBP\/P300 in rats and dogs","volume":"48","author":"Katavolos","year":"2020","journal-title":"Toxicol Pathol"},{"key":"2026021911383851700_bib75","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.immuni.2024.01.005","article-title":"Small-molecule CBP\/p300 histone acetyltransferase inhibition mobilizes leukocytes from the bone marrow via the endocrine stress response","volume":"57","author":"Jaschke","year":"2024","journal-title":"Immunity"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/doi\/10.1158\/0008-5472.CAN-25-3440\/3671780\/can-25-3440.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/86\/4\/1010\/3735720\/can-25-3440.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/86\/4\/1010\/3735720\/can-25-3440.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T16:38:59Z","timestamp":1771519139000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/86\/4\/1010\/772159\/Catalytic-Inhibition-of-p300-Preferentially"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":75,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,11,17]]},"published-print":{"date-parts":[[2026,2,16]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-25-3440","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.31345631","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31370732","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31370744","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31345661","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31370756","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31345613","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31345667","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31370750","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31345655","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31370762","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31345643","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31370774","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31370768","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31370714","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31370726","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31370738","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31345628","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31345616","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31345658","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31345664","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31345652","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31370765","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31370723","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31370777","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31345646","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31370771","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31345634","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31345622","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31345610","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31370741","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31370717","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31370729","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31370735","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31370747","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31370759","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31345649","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31345637","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31345625","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31345619","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31345607","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.8311814","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]}}}